| Popis: |
RAS mutations are the most common oncogenic mutations, present in >20% of human cancers. KRAS, the predominantly mutated isoform of RAS, is mutated in 40% of colorectal cancer (CRC), leading to constitutive activation of the MAPK (RAS/RAF) pathway and other downstream effectors. Due to the difficulty of targeting RAS, the first KRASG12C selective inhibitor has only been developed recently and approved by the FDA for non-small cell lung cancer. However, the inhibitor demonstrated much lower response rates in CRC ( Citation Format: Jun Tian, Ferran Fece de la Cruz, Kelly Burke, Tomonori Oka, Jacquelyn M. Curtis, Princy Sindurakar, Edmond Wong, Shadmehr Demehri, Arlene Sharpe, Ryan Corcoran. KRAS inhibition enhances immunogenicity of KRASG12C colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr LB352. |
